622 related articles for article (PubMed ID: 27997341)
21. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
[TBL] [Abstract][Full Text] [Related]
22. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome.
Al-Sukaiti N; Reid B; Lavi S; Al-Zaharani D; Atkinson A; Roifman CM; Grunebaum E
J Allergy Clin Immunol; 2010 Oct; 126(4):868-9. PubMed ID: 20810153
[No Abstract] [Full Text] [Related]
24. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.
Ang LW; Lai FY; Tey SH; Cutter J; James L; Goh KT
Epidemiol Infect; 2013 Aug; 141(8):1721-30. PubMed ID: 22999024
[TBL] [Abstract][Full Text] [Related]
26. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
Singh HK; Chiu YL; Wilkin T
AIDS Patient Care STDS; 2015 Sep; 29(9):461-4. PubMed ID: 26153909
[No Abstract] [Full Text] [Related]
27. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
Kakoulidou M; Ingelman-Sundberg H; Johansson E; Cagigi A; Farouk SE; Nilsson A; Johansen K
Vaccine; 2013 Jan; 31(4):711-7. PubMed ID: 23174196
[TBL] [Abstract][Full Text] [Related]
28. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
Llenas-García J; Rubio R; Hernando A; Arrazola P; Pulido F
AIDS Care; 2013 Aug; 25(8):980-9. PubMed ID: 23244745
[TBL] [Abstract][Full Text] [Related]
29. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
[TBL] [Abstract][Full Text] [Related]
32. Changes in the prevalence of the measles, rubella, varicella-zoster, and mumps virus antibody titers in Japanese pregnant women.
Hanaoka M; Hisano M; Watanabe N; Sugawara K; Kambe Y; Kanda E; Sago H; Kato T; Yamaguchi K
Vaccine; 2013 May; 31(19):2343-7. PubMed ID: 23523405
[TBL] [Abstract][Full Text] [Related]
33. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
Wanlapakorn N; Puenpa J; Thongmee T; Srimuan D; Thatsanathorn T; Vongpunsawad S; Poovorawan Y
Vaccine; 2020 May; 38(24):4016-4023. PubMed ID: 32331806
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
35. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.
Berry AA; Abu-Elyazeed R; Diaz-Perez C; Mufson MA; Harrison CJ; Leonardi M; Twiggs JD; Peltier C; Grogg S; Carbayo A; Shapiro S; Povey M; Baccarini C; Innis BL; Henry O
Hum Vaccin Immunother; 2017 Jul; 13(7):1516-1522. PubMed ID: 28481690
[TBL] [Abstract][Full Text] [Related]
36. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
37. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
Molyneaux PJ; Mok JY; Burns SM; Yap PL
J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
[TBL] [Abstract][Full Text] [Related]
38. M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.
Wiedmann RT; Reisinger KS; Hartzel J; Malacaman E; Senders SD; Giacoletti KE; Shaw E; Kuter BJ; Schödel F; Musey LK
Vaccine; 2015 Apr; 33(18):2132-40. PubMed ID: 25796337
[TBL] [Abstract][Full Text] [Related]
39. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
40. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
